We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+24.92%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$9.73M
(+8.4%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
177.31%
Top 10 Holdings %
Top 10 Hldgs %
37.67%
Holding
493
New
153
Increased
113
Reduced
67
Closed
127
Top Buys
| 1 |
Procter & Gamble
PG
|
+$3.82M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$2.47M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$2M |
| 4 |
Ulta Beauty
ULTA
|
+$1.86M |
| 5 |
MON
Monsanto Co
MON
|
+$1.82M |
Top Sells
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$7.18M |
| 2 |
Biogen
BIIB
|
+$4.33M |
| 3 |
Cal-Maine
CALM
|
+$3.64M |
| 4 |
Apple
AAPL
|
+$2.74M |
| 5 |
ALR
Alere Inc
ALR
|
+$2.22M |
Sector Composition
| 1 | Healthcare | 39.95% |
| 2 | Consumer Staples | 5.72% |
| 3 | Consumer Discretionary | 5.14% |
| 4 | Technology | 3.35% |
| 5 | Materials | 2.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Vertex Pharmaceuticals
VRTX
$123B
| $584K | 0.46% |
+6,694
| New | +$633K |
|
52
Heron Therapeutics
HRTX
$90.1M
| $516K | 0.41% |
29,937
+24,781
| +481% | +$460K |
|
53
Home Depot
HD
$347B
| $515K | 0.41% |
4,000
+500
| +14% | +$66.6K |
|
54
SCYNEXIS
SCYX
$44.5M
| $506K | 0.4% |
1,634
-315
| -16% | -$66.5K |
|
|
SPLK
55
DELISTED
Splunk Inc
SPLK
| $466K | 0.37% |
7,940
-1,287
| -14% | -$77.1K |
|
56
CALL
PTC Therapeutics
PTCT
$6.51B
| $451K | 0.36% |
100,400
+10,000
| +11% | +$81.3K |
|
57
Microsoft
MSFT
$2.98T
| $441K | 0.35% |
7,657
-5,688
| -43% | -$321K |
|
58
Dell
DELL
$253B
| $440K | 0.35% |
+32,817
| New | +$446K |
|
59
Larimar Therapeutics
LRMR
$381M
| $437K | 0.35% |
10,994
+8,916
| +429% | +$405K |
|
60
Alibaba
BABA
$282B
| $434K | 0.34% |
4,100
+2,900
| +242% | +$269K |
|
|
61
PUT
Vertex Pharmaceuticals
VRTX
$123B
| $429K | 0.34% |
+12,300
| New | +$1.16M |
|
|
ESPR
62
CALL
DELISTED
Esperion Therapeutics
ESPR
| $421K | 0.33% |
110,600
+25,100
| +29% | +$284K |
|
|
ISEE
63
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $417K | 0.33% |
55,100
+43,800
| +388% | +$2.47M |
|
|
NBRV
64
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $414K | 0.33% |
232
+34
| +17% | +$65.6K |
|
|
TSRO
65
DELISTED
TESARO, Inc.
TSRO
| $405K | 0.32% |
4,045
-2,963
| -42% | -$277K |
|
66
PUT
General Mills
GIS
$20.7B
| $393K | 0.31% |
68,600
+48,600
| +243% | +$3.38M |
|
67
PUT
United Therapeutics
UTHR
$22.5B
| $385K | 0.31% |
+21,000
| New | +$2.52M |
|
|
CYBR
68
DELISTED
CyberArk
CYBR
| $362K | 0.29% |
+7,300
| New | +$389K |
|
|
GWPH
69
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $362K | 0.29% |
78,900
+33,400
| +73% | +$3.19M |
|
|
ITCI
70
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $359K | 0.28% |
+18,000
| New | +$728K |
|
71
Charter Communications
CHTR
$16.4B
| $355K | 0.28% |
1,315
+240
| +22% | +$60.6K |
|
|
ISEE
72
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $355K | 0.28% |
17,000
+5,000
| +42% | +$282K |
|
73
CALL
Yum! Brands
YUM
$41.9B
| $352K | 0.28% |
66,073
+27,820
| +73% | +$1.78M |
|
74
KLA
KLAC
$287B
| $350K | 0.28% |
50,170
+33,000
| +192% | +$238K |
|
|
MNK
75
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $349K | 0.28% |
+5,004
| New | +$362K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q3 2016 Portfolio in Review
As of Q3 2016, FT Options held 493 positions worth $126M, up 8.4% from $116M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $224M of net new capital in Q3 2016, opening 153 new positions and adding to 113 existing holdings. Its largest new stake was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 41% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $2.74M trimmed.
- FT Options's largest Q3 2016 buy was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
- FT Options added most to Procter & Gamble in Q3 2016, an estimated $3.82M increase.
- FT Options's biggest Q3 2016 reduction was Apple, cutting an estimated $2.74M.
- FT Options fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $7.18M.
- FT Options's ten largest holdings make up 38% of its $126M portfolio in Q3 2016.
- FT Options opened 153 new positions and closed 127 in Q3 2016.
- FT Options's portfolio value rose 8.4% quarter-over-quarter to $126M.
Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.